(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 27 January 2005 (27.01.2005)

(10) International Publication Number WO 2005/007629 A1

(51) International Patent Classification7: A61K 31/445, A61P 29/00, 31/12

C07D 221/24,

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) international Application Number:

PCT/SE2004/001135

(22) International Filing Date:

14 July 2004 (14.07.2004)

(25) Filing Language:

English

(26) Publication Language:

(30) Priority Data: 0302090-6

SE 16 July 2003 (16.07.2003)

English

(71) Applicant (for all designated States except US): AS-TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): BROWN, Dearg [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). CUMMING, John [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). TUCKER, Howard [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
- (74) Agent: ASTRAZENECA; Global Intellectual Property, S-151 85 Södertälje (SE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, I.V, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI., SY, TJ, TM,

kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TX, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, FS, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PI, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,

(84) Designated States (unless otherwise indicated, for every

GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

as to applicant's entitlement to apply for and be granted a pasent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA. CH. CN. CO. CR. CU. CZ. DE. DK. DM. DZ. EC. EE. EG, ES, FI, GB, GD, GE, GII, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA. MD. MG. MK. MN. MW. MX. MZ. NA. NI. NO. NZ. OM. PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM. TN. TR. TT. TZ. UA. UG. UZ. VC. VN. YU. ZA. ZM. ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA. SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE. BG, CH. CY, CZ, DE, DK. EE, ES, FI, FR. GB, GR, HU, IE. IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, MI., MR, NE. SN, TD, TG)

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PIPERIDINE OR 8-AZA-BICYCLO[3.2.1]OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

(57) Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, A and n are as defined; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).